Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,829 Lymphoma
clinical trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Expanded Access Protocol for Tabelecleucel in Subjects With EBV-Associated Viremia or Malignancies
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Lymphoma Clinical Trial
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Maywood, IL
Click here to add this to my saved trials
Lymphoma Clinical Trial
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
New Haven, CT
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fargo, ND
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Traverse City, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
Oncology Clinical Trial
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oncology, Psychiatry / Psychology Clinical Trial
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Oncology, Psychiatry / Psychology Clinical Trial
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Status: Enrolling
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Non-Hodgkin's Lymphoma Clinical Trial
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Louisville, KY
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Allo HSCT Using RIC for Hematological Diseases
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Peripheral T-Cell Lymphoma Clinical Trial
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Atlanta, GA
Click here to add this to my saved trials
Peripheral T-Cell Lymphoma Clinical Trial
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Dallas, TX
Click here to add this to my saved trials
Peripheral T-Cell Lymphoma Clinical Trial
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Peripheral T-Cell Lymphoma Clinical Trial
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Westwood, KS
Click here to add this to my saved trials
Oncology Clinical Trial
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Seattle, WA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Bethesda, MD
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Aurora, CO
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Malignant Neoplasms Clinical Trial
A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Chicago, IL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Fairway, KS
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
New Haven, CT
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Advanced Solid Tumors or Lymphomas Clinical Trial
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Chicago, IL
Click here to add this to my saved trials
Advanced Solid Tumors or Lymphomas Clinical Trial
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Nashville, TN
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New Haven, CT
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Charlotte, NC
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Jackson, MS
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Oakland, CA
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Detroit, MI
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fairfax, VA
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Madera, CA
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Valhalla, NY
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Washington DC,
Click here to add this to my saved trials
Hodgkin Disease Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Wilmington, DE
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Austin, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Birmingham, AL
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Burlington, VT
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Hartford, CT
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Portland, OR
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Akron, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Albany, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Allentown, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Columbia, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Danville, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
El Paso, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Greenville, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Iowa City, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Lubbock, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Morristown, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Newark, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Orlando, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Spokane, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Syracuse, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Washington DC,
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Portland, OR
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Seattle, WA
Click here to add this to my saved trials
Lymphoma, Non-Hodgkin Clinical Trial
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Bethesda, MD
Click here to add this to my saved trials
Lymphoma, Non-Hodgkin Clinical Trial
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Sacramento, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Denver, CO
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
New Haven, CT
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Baltimore, MD
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Long Beach, CA
Click here to add this to my saved trials
1 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 98